Real-World data: takhzyro cuts HAE attacks in saudi patients
NCT ID NCT07263685
First seen Jan 05, 2026 · Last updated May 17, 2026 · Updated 23 times
Summary
This study looks at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who have been taking Takhzyro for at least 6 months to prevent swelling attacks. Researchers want to see if the drug reduces disease activity and improves quality of life in real-world settings. No new treatments are given; only existing data is reviewed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
King Faisal Specialist Hospital and Research Centre
RECRUITINGRiyadh, 12713, Saudi Arabia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.